Furthermore, in the CANVAS study, early reductions in both TNFR1 and TNFR2 during treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin were associated with a reduced risk of DKD progression (39). Here, SLC5A2 is linked to diabetic kidney disease.